About Otsuka Group
The Otsuka group of companies is a global enterprise with central hubs for R&D and commercialization in the US, Europe, and Asia. Our approximately 47,000 employees across 200 companies in 33 countries and regions take on challenges across various fields and themes to help fulfill the universal wish of people to be healthy. As one of the group companies, Otsuka Pharmaceutical Co., Ltd. pursues external collaborations as a key strategy to advance innovation.
* Rest of the world
Otsuka's Partnering Focus
Leverage strategic partnership to address important unmet medical needs in
neuroscience, nephrology, and oncology.
- Unique and novel mechanism of action
- Significant differentiation with competitors
- Global Asset
Neuroscience / Kidney diseases / Autoimmune /
- Japan / Asia Asset
Above mentioned plus:
Gastrointestinal disorders / Cardiovascular diseases / Ophthalmology / Dermatology
- Excluding US
Target Development Stage
- Global Asset
Preclinical (within 2 years to IND)
P1, P2, P3, Filing, Approval, Launch
- Japan/Asia Asset
POC proven in US / EU
- Small molecules
- Large molecules
- Allogeneic cell therapy
- Nucleic acid
- Gene therapy
- Fill out the form
- Confirm your inquiry
Otsuka Pharmaceutical welcomes your questions and feedback. Please fill out the form below, before proceeding to "Confirm your inquiry" step.
Fields marked with * are mandatory.
Please note that we may not be able to respond to your online inquiry. Also we may need some time to respond to your inquiry. We appreciate for your patience.